T cells key to COVID-19 vaccination efforts
Experts discuss shortcomings of current COVID-19 vaccines in people with cancer while highlighting possibilities of T-cell activation.
Progress Against Cancer
Experts discuss shortcomings of current COVID-19 vaccines in people with cancer while highlighting possibilities of T-cell activation.
From the AACR Annual Meeting, “practice changing” immunotherapy effective against lung cancer, and CAR T-cell therapy targets solid tumors.
Excitement and emotion ran high Sunday morning as Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research (AACR), officially launched the Annual Meeting 2022 Sunday in New Orleans....
CAR T-cell therapy approved for relapsed large B-cell lymphoma, and screening catches lung cancer earlier, although disparities persist
Chemo brain may provide clues for long-haul COVID-19, and researchers analyze relationship between obesity and cancer.
The FDA approved the cellular immunotherapy axicabtagene ciloleucel for second-line treatment of patients with large B-cell lymphoma. The U.S. Food and Drug Administration (FDA) has approved axicabtagene ciloleucel (Yescarta) for the treatment of adult...
In 2015, NFL running back Brandon Bolden was having an incredible season with the New England Patriots. That year, he helped his team to a Super Bowl win against the Seattle Seahawks. That...
For more than 20 years, the Scientist↔Survivor Program (SSP) has played a vital role in the American Association for Cancer Research (AACR) Annual Meeting. This year, as we excitedly plan for a return to...
Pilot program emphasizes standards to streamline patient care.
Expansions in coverage and eligibility through the Affordable Care Act have made Medicaid a lifeline for many people with cancer, but benefits vary from state to state.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More